Ghost Tree Capital LLC Has Lifted Its Ptc Therapeutics INC (PTCT) Stake by $15.68 Million

PTC Therapeutics, Inc. (NASDAQ:PTCT) LogoInvestors sentiment increased to 1.77 in Q2 2018. Its up 0.51, from 1.26 in 2018Q1. It increased, as 18 investors sold PTCT shares while 34 reduced holdings. 47 funds opened positions while 45 raised stakes. 38.38 million shares or 0.29% less from 38.49 million shares in 2018Q1 were reported. 185,830 were accumulated by Comml Bank Of New York Mellon. Mackay Shields Ltd Liability Corp invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Alliancebernstein LP has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 70,350 shares. Renaissance Technology Lc, a New York-based fund reported 219,200 shares. Swiss Bankshares holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 61,465 shares. Rhumbline Advisers accumulated 0% or 43,696 shares. Prudential accumulated 83,890 shares. 103,959 were accumulated by Prelude Mgmt Ltd Limited Liability Company. Kepos LP stated it has 0.06% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Acadian Asset Mngmt Ltd Liability Com owns 2,437 shares. Teacher Retirement Systems Of Texas reported 7,165 shares. Morgan Stanley has 575,189 shares for 0.01% of their portfolio. Principal Fincl Grp has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Deutsche National Bank & Trust Ag owns 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 189,350 shares. Hsbc Hldgs Public Ltd Com owns 12,921 shares.

Since June 19, 2018, it had 0 buys, and 1 insider sale for $966,240 activity.

Ghost Tree Capital Llc increased its stake in Ptc Therapeutics Inc (PTCT) by 237.5% based on its latest 2018Q2 regulatory filing with the SEC. Ghost Tree Capital Llc bought 475,000 shares as the company’s stock rose 24.42% with the market. The hedge fund held 675,000 shares of the health care company at the end of 2018Q2, valued at $22.77M, up from 200,000 at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Ptc Therapeutics Inc for a number of months, seems to be bullish on the $1.68 billion market cap company. The stock decreased 7.05% or $2.53 during the last trading session, reaching $33.36. About 866,056 shares traded or 2.81% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 128.81% since December 8, 2017 and is uptrending. It has outperformed by 113.19% the S&P500.

Ghost Tree Capital Llc, which manages about $339.79 million US Long portfolio, decreased its stake in Iovance Biotherapeutics Inc by 640,000 shares to 360,000 shares, valued at $4.61M in 2018Q2, according to the filing. It also reduced its holding in Immunomedics Inc (NASDAQ:IMMU) by 600,000 shares in the quarter, leaving it with 1.25 million shares, and cut its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT).

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “PTC Therapeutics to acquire Agilis Biotherapeutics for $200M; shares up 8.5% – Seeking Alpha” on July 19, 2018, also with their article: “Report: Exploring Fundamental Drivers Behind JB Hunt Transport Services, Kura Oncology, National Beverage, Benefitfocus, PTC Therapeutics, and Walgreens Boots Alliance — New Horizons, Emerging Trends, and Upcoming Developments – Nasdaq” published on November 30, 2018, published: “What’s Behind PTC Therapeutics’ 10% Rally Today – The Motley Fool” on July 20, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: and their article: “PTC Therapeutics Surges On Positive Outcome From Rare Disease Study – Seeking Alpha” published on June 19, 2018 as well as‘s news article titled: “Don’t Get Too Excited About PTC Therapeutics (Yet) – Motley Fool” with publication date: June 20, 2018.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. PTC Therapeutics had 12 analyst reports since June 18, 2018 according to SRatingsIntel. The company was upgraded on Monday, June 18 by William Blair. The rating was upgraded by Barclays Capital to “Equal-Weight” on Wednesday, June 20. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Outperform” rating given on Tuesday, November 6 by RBC Capital Markets. As per Tuesday, July 31, the company rating was maintained by Bank of America. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Overweight” rating by Cantor Fitzgerald on Monday, November 12. Barclays Capital maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, August 8 with “Equal-Weight” rating. The firm has “Buy” rating given on Tuesday, July 24 by Citigroup. The firm has “Equal-Weight” rating given on Tuesday, November 6 by Barclays Capital. The firm has “Outperform” rating by RBC Capital Markets given on Monday, June 18. The firm has “Outperform” rating by Credit Suisse given on Wednesday, September 5.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.